Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 141.30 4.40
Tata Mot 428.65 4.24
Bhel 181.05 3.10
Tata Stl 418.80 1.22
Ntpc Ltd 123.05 0.37
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Arvind Remedies Limited
Arvind Remedies Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:531823NSE:ARVINDREMBloomberg:ARR@INReuters:ARRE.BO
Market Lot: 1Face Value: 10ISIN Demat: INE211C01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
18-NOV-13 Arvind Remedies (ARL), a leading producer of branded and generic pharmaceutical products has made developing a new drug for viral diseases in collaboration with various leading institutes. 18-OCT-13 Arvind Remedies (ARL) a leading producer of branded and generic pharmaceutical products has signed a Memorandum of Understanding (MoU) with four institutions namely Banaras Hindu University, Adesh University, SRM University and Genome Fo...   More..
Business Profile Future Plans
CEO Talk
Arvind Remedies expects its turnover to grow 20-30 per cent in the current fiscal, while net profit is likely to jump substantially. The company`s herbal division is expected to register a 40 per cent growth in turnover during the next three years, while allopathic division will grow 15 per cent.   Arvind Shah
One To One
Recent news
Latest News
Arvind Remedies to formulate new drug for viral diseases  -IRIS 18-Nov-13
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 6361.646632.604365.67
Other Income3.405.933.88
Total Income6365.046638.534369.54
Cost of goods sold5124.425305.283688.43
OPBDIT1240.621333.25681.12
PAT482.64406.17194.10
Gross Block---
Equity capital681.26482.30482.30
EPS (Rs.)-8.420.40
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-0.26 - 4.764.50 - 7.50
Debt / Equity (x)---
Operating margin (% of OI)19.520.115.6
Net margin (% of OI) 7.6 6.1 4.4
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
190, Poonamallee High Road
Chennai
Tamil Nadu-600 084
PHONE
(044) 2641 4788/ 89
FAX
(044) 2642 3296
 
Board of Directors
Board Meetings
Date Purpose
06-MAY-14 Dividend & Audited Results
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer